Colin Baigent

Q: What Schools Are Affiliated With Colin Baigent

Colin Baigent is affiliated with the following schools: University of Oxford, Nuffield Department of Population Health

Colin Baigent's AcademicInfluence.com Rankings

Colin Baigent

Medical

#1728

World Rank

#2098

Historical Rank

Epidemiology

#296

World Rank

#313

Historical Rank

medical Degrees

Download Badge

Medical

Colin Baigent's Degrees

PhD Epidemiology University of Oxford

Why Is Colin Baigent Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Colin Baigent is a British academic physician and cardiovascular epidemiologist. He is a professor of epidemiology, Director of the Medical Research Council Population Health Research Unit at the University of Oxford, and deputy director of the Clinical Trial Service Unit and Epidemiological Studies Unit , part of Oxford Population Health . His work is focused in the design and coordination of large-scale randomised trials and the use of meta-analysis to assess the efficacy and safety of drugs for the prevention of cardiovascular disease or premature death.

(See a Problem?)

Colin Baigent's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins (2005) (6375)
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients (2002) (5918)
Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. (2019) (3648)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. (2010) (3183)
Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988) (2755)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial (2011) (2093)
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. (2009) (1857)
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials (2014) (1828)
ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction (1995) (1755)
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. (2008) (1647)
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. (2012) (1436)
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials (2013) (1418)
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials (2006) (1399)
Interpretation of the evidence for the efficacy and safety of statin therapy (2016) (1290)
Low-dose aspirin for the prevention of atherothrombosis. (2005) (1121)
Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials (2015) (999)
Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (748)
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus (2018) (735)
Aspirin in patients undergoing noncardiac surgery. (2014) (686)
Revascularization versus medical therapy for renal-artery stenosis. (2009) (647)
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. (1998) (632)
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019) (630)
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment (2013) (605)
Premature cardiovascular disease in chronic renal failure (2000) (582)
COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England (2020) (464)
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data (2014) (449)
Effects of n‐3 Fatty Acid Supplements in Diabetes Mellitus (2018) (441)
ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither (1998) (422)
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (2004) (419)
Cholesterol and the risk of renal dysfunction in apparently healthy men. (2003) (409)
Vitamin K antagonists in heart disease: Current status and perspectives (Section III) (2013) (385)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Study of Heart and Renal Protection (SHARP). (2003) (358)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD (2020) (310)
Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. (2004) (302)
Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. (2005) (298)
Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. (1997) (297)
Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy (2012) (293)
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. (2012) (265)
Parenteral anticoagulants in heart disease: Current status and perspectives (Section II) (2013) (251)
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data (2002) (246)
Antiplatelet agents for the treatment and prevention of atherothrombosis. (2011) (220)
Trials: the next 50 years (1998) (214)
Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. (2016) (207)
Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials (2013) (203)
Diabetes and Cause-Specific Mortality in Mexico City. (2016) (197)
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials (1996) (197)
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. (2005) (189)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study (2018) (184)
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) (181)
Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children (1996) (177)
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials (2016) (173)
General mechanisms of coagulation and targets of anticoagulants (Section I) (2013) (172)
Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collab (2000) (161)
Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study (2021) (160)
Statins and diabetes – Authors' reply (2008) (160)
Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study (2010) (160)
Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis (2016) (158)
Thigh-Length Versus Below-Knee Stockings for Deep Venous Thrombosis Prophylaxis After Stroke (2010) (145)
Ensuring trial validity by data quality assurance and diversification of monitoring methods (2008) (145)
Anticoagulants in heart disease: current status and perspectives. (2007) (143)
Effects of lowering LDL cholesterol on progression of kidney disease. (2014) (140)
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials (2018) (132)
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial (2014) (129)
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. (2017) (127)
Statins for people at low risk of cardiovascular disease – Authors' reply (2012) (123)
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis. (2018) (116)
Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies (2018) (115)
Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. (2003) (113)
Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. (2001) (111)
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. (2006) (108)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised controlled trials of statins (vol 366, pg 1267, 2005) (2008) (104)
Analyses of cancer data from three ezetimibe trials. (2008) (100)
Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. (1998) (99)
Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial (2019) (98)
Randomized clinical trials--removing unnecessary obstacles. (2013) (97)
Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial (2019) (96)
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial (2018) (94)
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial (2018) (94)
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference (2017) (94)
Empagliflozin in Patients with Chronic Kidney Disease (2022) (86)
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. (2018) (83)
Neprilysin inhibition in chronic kidney disease (2014) (83)
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis (2011) (77)
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up (2021) (77)
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? (2015) (73)
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial (2015) (72)
Role of aspirin in primary prevention of cardiovascular disease (2019) (71)
The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. (2016) (68)
Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. (2009) (67)
Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP) (2014) (63)
Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies (2016) (63)
Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis (2021) (60)
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP) (2016) (60)
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP) (2016) (60)
Nonsteroidal Anti-Inflammatory Drugs and the Heart (2014) (55)
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease (2016) (55)
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study (2018) (55)
The role of lipoprotein (a) in chronic kidney disease (2018) (54)
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial (2019) (53)
Sensible guidelines for the conduct of large randomized trials (2008) (53)
Novel preservation solution permits 24-hour preservation in rat and baboon cardiac transplant models. (1993) (51)
Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study (2018) (50)
Evidence for the Prevention and Treatment of Stroke in Dialysis Patients (2014) (49)
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up (2021) (49)
The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action (2021) (48)
Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome (2016) (48)
Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin receptor antagonists in Marfan syndrome, based on individual patient data: A report from the Marfan Treatment Trialists' Collaboration (2015) (45)
Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomised double-blind trial [accepted manuscript] (2018) (43)
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis (2021) (42)
The 2014 International Workshop on Alport Syndrome (2014) (41)
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes. (2020) (38)
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data (2016) (35)
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes (2012) (35)
Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD (2016) (34)
Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP). (2017) (33)
Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. (2019) (32)
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post‐PRECISION: What We Thought We Knew Then and What We Think We Know Now (2017) (32)
Blood pressure lowering and cardiovascular risk – Authors' reply (2014) (32)
Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials (2018) (31)
Chronic kidney disease, heart failure and neprilysin inhibition (2019) (30)
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease (2017) (30)
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation (2017) (29)
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation (2017) (29)
Cross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis Patients (2007) (29)
Effects of oral anticoagulation for atrial fibrillation after spontaneous intracranial haemorrhage in the UK: a randomised, open-label, assessor-masked, pilot-phase, non-inferiority trial (2021) (28)
Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis (2013) (28)
Should we reduce blood cholesterol to prevent cardiovascular disease among patients with chronic renal failure? (2000) (28)
Aspirin for everyone older than 50?: AGAINST (2005) (27)
A Practical Method of Measuring Glomerular Filtration Rate by Iohexol Clearance Using Dried Capillary Blood Spots (2007) (27)
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial (2022) (27)
Should We Increase GFR with Bardoxolone in Alport Syndrome? (2018) (27)
Article makes simple errors and could cause unnecessary deaths (2002) (26)
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhibitors (2021) (26)
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis (2021) (25)
Which cardiovascular risk factors matter in chronic kidney disease? (2006) (24)
CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: Misleading Associations between Cholesterol and Vascular Outcomes in Dialysis Patients: The Need for Randomized Trials (2007) (24)
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (2016) (24)
Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP) (2016) (24)
Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men (2010) (24)
The need for large-scale randomized evidence. (1997) (23)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials (2022) (23)
Protocol for analyses of adverse event data from randomized controlled trials of statin therapy (2016) (23)
Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom (2020) (23)
Statin therapy in kidney disease populations: potential benefits beyond lipid lowering and the need for clinical trials (2004) (22)
Exploring the role and function of trial steering committees: results of an expert panel meeting (2015) (22)
Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol (2013) (22)
The urgent need to vaccinate dialysis patients against SARS-CoV-2: A call to action (2021) (22)
Biliary Tract and Liver Complications in Polycystic Kidney Disease. (2017) (22)
Impact of CKD on Household Income (2017) (20)
B vitamins for the prevention of vascular disease: insufficient evidence to justify treatment. (2007) (20)
Impact of CKD on Household Income (2017) (20)
Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy (2018) (19)
Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)) (2019) (19)
The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. (2014) (19)
Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial (2018) (18)
Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio. (2016) (18)
Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis (2006) (17)
Prevention: Aspirin in primary prevention—good news and bad news (2012) (17)
A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease (2017) (17)
[Expert consensus document on the use of antiplatelet agents]. (2004) (16)
Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials (2009) (16)
Conventional and Genetic Evidence on the Association between Adiposity and CKD. (2020) (16)
Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials (2021) (13)
Cardiovascular aspects of kidney disease (2012) (12)
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis (2021) (12)
Misrepresentation of statin safety evidence (2014) (11)
Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials (2022) (11)
Cardiovascular aspects of chronic kidney disease (2011) (11)
The struggle for life: A psychological perspective of kidney disease and transplantation (2004) (10)
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection (2017) (10)
Selective COX-2 inhibitors: where do we go from here? (2008) (10)
Statins: are any questions unanswered? (2006) (10)
Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection (2017) (10)
Efficacy and safety of cholesterol-lowering treatment – Authors' reply (2006) (10)
Large-scale randomized evidence: Trials and meta-analyses of trials (2010) (8)
The adverse effects of different doses of aspirin: a systematic overview of randomised trials and observational studies (2000) (8)
Thrombolysis in acute stroke – Authors' reply (2015) (8)
Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. (2019) (7)
Benefit of heparin plus aspirin vs aspirin alone in unstable angina. (1996) (7)
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease (2021) (7)
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis (2022) (7)
Are statins useful in patients with advanced chronic kidney disease? - Authors' reply. (2016) (7)
Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank (2020) (6)
Erratum to "2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. (2019) (6)
CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research (2022) (6)
Pragmatic Trials - Need for ADAPTABLE Design. (2021) (6)
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease (2019) (6)
CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research (2022) (6)
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease (2019) (6)
Relationship between anaemia, coagulation parameters during pregnancy and postpartum haemorrhage at childbirth: a prospective cohort study (2021) (5)
Cardiovascular risk factors in patients with chronic renal failure (1997) (5)
LATE BENEFIT AND EARLY HAZARD ASSOCIATED WITH FIBRINOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS FROM 6 LARGE RANDOMIZED CONTROLLED TRIALS (1992) (5)
Maternal and perinatal Health Research Collaboration, India (MaatHRI): methodology for establishing a hospital-based research platform in a low and middle income country setting. (2020) (5)
Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. (2021) (5)
Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies? (2017) (5)
Cholesterol metabolism and statin effectiveness in hemodialysis patients. (2015) (5)
Coxibs and traditional NSAIDs for pain relief – Authors' reply (2014) (5)
Clinical Trials and Meta-Analysis (2010) (5)
Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study. (2002) (5)
Aspirin for Disease Prevention: Public Policy or Personal Choice? (2016) (4)
ESC position paper Anticoagulants in heart disease : current status and perspectives ‡ (2007) (4)
Renal function: an emerging risk factor for cardiovascular disease? (2001) (4)
Randomized Trials of Antiplatelet Therapy (1999) (4)
Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial (2020) (4)
Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD) (2020) (4)
Antiplatelet therapy: Aspirin for asymptomatic atherosclerosis? (2010) (4)
Lessons from the controversy over statins – Authors’ reply (2016) (3)
Immediate aspirin for suspected ischaemic stroke (1999) (3)
Safety of metformin in Type 2 diabetes mellitus (1999) (3)
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes Analysis of 9 Trials the Stroke Thrombolysis Trialists’ Collaborators (2016) (3)
Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies (2016) (3)
Cholesterol and lipids (2008) (3)
Blood pressure and the risk of recurrent vascular disease (1998) (3)
What is the association of COVID-19 with heart attacks and strokes? (2021) (3)
Benefits of lowering cholesterol in chronic kidney disease – Authors' reply (2011) (2)
Clopidogrel reduced stroke, MI, and vascular death compared with aspirin (1997) (2)
Variability in aspirin efficacy: all in the genes? (2019) (2)
Maternal and perinatal Health Research Collaboration, India (MaatHRI): methodology for establishing a hospital-based research platform in a low and middle income country setting (2021) (2)
Air pollution and traffic noise: do they cause atherosclerosis? (2014) (2)
Investigating modifications to participant information materials to improve recruitment into a large randomized trial (2019) (2)
Preventing unintended pregnancy: let us count the ways (2006) (2)
Effect of statins on ventricular arrhythmic events: a collaborative meta-analysis of randomised controlled trials (2009) (2)
Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses (2022) (2)
Impact of renal function on the effects of reducing LDL cholesterol with statin-based regimens: meta-analysis of individual data from 28 randomised trials. (2016) (2)
CANCER AND CHRONIC KIDNEY DISEASE: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF 33,618 PARTICIPANTS (2014) (2)
Safety and efficacy of statins – Authors' reply (2017) (2)
Efficacy and safety of more intensive lowering of LDL cholesterol – Authors' reply (2011) (1)
Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients (2023) (1)
IS100 THE NEED FOR LARGE-SCALE RANDOMISED EVIDENCE (1997) (1)
Exploring the role and functionality of trial steering committees (2015) (1)
Review: NSAIDs increase GI and CV events; coxibs increase mortality (2013) (1)
Maternal and perinatal Health Research Collaboration, India (MaatHRI): methodology for establishing a hospital-based research platform in a low and middle income country setting. (2020) (1)
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study (2022) (1)
Focused cardiac ultrasound to guide the diagnosis of heart failure in pregnant women in India. (2022) (1)
Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology (2022) (1)
Efficacy of aspirin in people with diabetes: an individual participant data meta-analysis of 26 randomised trials (2014) (1)
Anticoagulants in Heart Disease Position Paper Syndromes: ESC Working Group on ThrombosisTask Force on New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary (2012) (1)
The control of weeds in field crops (1951) (1)
Aspirin in the primary prevention of vascular disease – ATT secretariat's reply (2009) (1)
Randomization is essential for progress in transplant medicine. (2008) (1)
The Safety and Efﬁcacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis (1)
Maternal and perinatal Health Research Collaboration, India (MaatHRI): methodology for establishing a hospital- based research platform in a low and middle income country setting [version 3; peer review: 2 approved] (2021) (1)
Thematic Lipoprotein (a): Coming of Age at Last The role of lipoprotein (a) in chronic kidney disease (2018) (0)
Impact of cardiovascular events on primary and hospital care costs: findings from UK Biobank study (2022) (0)
Serum cholesterol and the risk of renal dysfunction in men. (2002) (0)
JAMA Cardiology List of Peer Reviewers. (2017) (0)
Antiplatelet prophylaxis. The same for men and women [2] (1994) (0)
International register of current protocols in childhood acute lymphoblastic leukaemia (ALL) (1995) (0)
Meta-analysis of randomised trials drugs increase the risk of atherothrombosis? traditional non-steroidal anti-inflammatory Do selective cyclo-oxygenase-2 inhibitors and (2006) (0)
Questioning statin therapy for older patients – Authors' reply (2020) (0)
Cost-effectiveness of statin therapy in categories of patients in the UK (2022) (0)
Department of Error (2016) (0)
ELECTIVE CONVERSION TO SIROLIMUS VS. CONTINUED TACROLIMUS IN KIDNEY TRANSPLANTATION (THE 3C STUDY): RESULTS OF A RANDOMIZED TRIAL (2018) (0)
Benefit of aspirin plus angiotensin-converting enzyme inhibitor. (2001) (0)
Impact of the COVID-19 pandemic on admission rates for, and management of, acute coronary syndromes in England. (2020) (0)
P70 Calibrating Cardiovascular Disease Policy Model Using Large Cohort Data (2022) (0)
CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research (2022) (0)
Trials of antiplatelet therapy: Authors' reply. (1994) (0)
Recent advances in spraying procedure (1952) (0)
Anesthesia in neonatal cardiac surgery. (1992) (0)
A novel approach using hand-held echocardiography to guide the diagnosis of heart failure in pregnant women in a low-resource setting; Maternal and Perinatal Health Research Collaboration (2020) (0)
TRIALS OF ANTIPLATELET THERAPY - REPLY (1994) (0)
Maternal and perinatal Health Research Collaboration, India (MaatHRI): establishing a hospital-based international collaborative research platform (2020) (0)
The effect of delay, age, and stroke severity on the risk of intracranial hemorrhage after intravenous alteplase for acute stroke: An individual patient data meta-analysis (2015) (0)
A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts (2021) (0)
Relationship between Anaemia, Coagulation Parameters During Pregnancy and Blood Loss in Childbirth: A Prospective Cohort Study in India (2020) (0)
Epidemiological data on the use of traditional anticoagulants in cardiovascular disease (2018) (0)
Antiplatelet prophylaxis: Authors' reply (1994) (0)
Alemtuzumab induction therapy in kidney transplantation – Authors' reply (2015) (0)
Re: Chronic aspirin therapy is effective - if you massage the data sufficiently (2017) (0)
Impact of prior myocardial infarction and vascular disease on the risk of subsequent cardiac events among 68 730 patients commencing dialysis. (2002) (0)
Reducing Cardiovascular Events in Patients with Chronic Kidney Disease (2011) (0)
Effects of streptokinase in patients presenting within 6 hours of prolonged chest pain with ST segment depression. (1995) (0)
OC04_04 Extreme Cardiac and Renal Mortality From Diabetes: 12-Year Blood-Based Prospective Study of 150,000 Mexican Adults (2016) (0)
Aspirin in the primary prevention of vascular disease. Authors' reply (2009) (0)
Ticlopidine reduced the incidence of late occlusion of below-the-knee saphenous vein grafts. (1998) (0)
CONVENTIONAL AND GENETIC EVIDENCE ON THE ASSOCIATION BETWEEN ADIPOSITY AND CHRONIC KIDNEY DISEASE (2020) (0)
Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors (2022) (0)
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK (2023) (0)
The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study (2018) (0)
ELEVATED LEVELS OF ASYMMETRIC DIMETHYLARGININE (ADMA) AND SYMMETRIC DIMETHYLARGININE (SDMA) CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS (2005) (0)
Department of Error (2016) (0)
Edinburgh Research Explorer Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke (2017) (0)
Benefits of reducing LDL cholesterol among 18,686 patients with diabetes: Meta-analysis of 14 radomized trials of a statin versus control (2006) (0)
Efficacy and safety of cholesterol-lowering treatment—authors' reply [letter] (2006) (0)
Benefit accrual with cardiovascular disease prevention and effects of discontinuation: a modelling study (2022) (0)
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomisation study (2022) (0)
The Editorial Office thanks the following colleagues for reviewing papers for the period of 1 November 2000 to 31 October 2001 (2002) (0)
IMPACT OF EDUCATIONAL ATTAINMENT ON HEALTH OUTCOMES IN MODERATE-TO-SEVERE CHRONIC KIDNEY DISEASE (2015) (0)
Emberson, J. et al. (2014) Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data (2014) (0)
Increasing blood pressure was associated with increased risk of stroke in patients with cerebrovascular disease. (1997) (0)
Thanks to Reviewers2005 (2005) (0)
Use of gel-based separator tubes to stabilise phosphate in mailed blood samples. (2015) (0)
Apolipoprotein B, Triglyceride-rich Lipoproteins, and Risk of Cardiovascular Events in Persons with Chronic Kidney Disease (2019) (0)
Effects of alteplase for acute stroke according to criteria defining the EU and US marketing authorizations: individual-patient-data meta-analysis of randomized trials (2017) (0)
Results of a Large Randomized Controlled Trial of Alemtuzumab‐Versus Basiliximab‐Based Induction Therapy in Kidney Transplantation.: Abstract# A2986 (2014) (0)
Are statins effective in preventing coronary artery disease (2006) (0)
SERUM LIPIDS DO NOT PREDICT CARDIOVASCULAR OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS (2005) (0)
Thanks to Reviewers (2019) (0)
Papillary Muscle Hypothesis of Idiopathic Left Ventricular Tachycardia (2016) (0)
Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease (2019) (0)
ELEVATED LEVELS OF N-TERMINAL BRAIN NATRIURETIC PEPTIDE AND TROPONIN T CORRELATE WITH KIDNEY FUNCTION AND PREDICT OUTCOMES IN CHRONIC KIDNEY DISEASE PATIENTS (2005) (0)

This paper list is powered by the following services:

Other Resources About Colin Baigent

en.wikipedia.org

What Schools Are Affiliated With Colin Baigent?

Colin Baigent is affiliated with the following schools:

Colin Baigent's Academic­Influence.com Rankings